Urol. praxi. 2017;18(2):64-68 | DOI: 10.36290/uro.2018.041

New diagnostic options and prognosis prediction of urinary bladder cancer

MUDr. Milan Král, Ph.D., MUDr. David Hradil, MUDr. Šárka Kudláčková, MUDr. Aleš Vidlář, Ph.D., FEBU, doc. MUDr. Vladimír Študent, Ph.D.
Urologická klinika LF UP a FN Olomouc

High cancer recurrence is typical for urinary bladder tumors regardless of radically performed transurethral surgery. The explanation lies in genetic information of urothelial cells but also in unrevealing all malignant areas in the bladder during cystoscopy or transurethral resection. Diagnostic improvement can be reached by using new endoscopic techniques which precise resolution between normal and pathological bladder mucosa. Further improvement and individualisation of the therapy can be reached by prognostic markers analysis which can identify metastatic status of the disease e.g. by using circulating tumor cells dispite invisible metastasis on imaging methods. In the future, we should be able to define patients who would profit from early start of multimodal therapy and, concurently, we could increase the chance of local cancer control and curability of combined surgical and oncological therapy.

Keywords: bladder cancer, diagnostic, narrow band imaging, photodynamic diagnostic, markers

Received: August 7, 2018; Accepted: November 7, 2018; Prepublished online: November 7, 2018; Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Král M, Hradil D, Kudláčková Š, Vidlář A, Študent V. New diagnostic options and prognosis prediction of urinary bladder cancer. Urol. praxi. 2017;18(2):64-68. doi: 10.36290/uro.2018.041.
Download citation

References

  1. Babjuk M, Böhle A, Burger M, et al. Guidelines for non-muscle invasive bladder cancer [online]. Dostupné z WWW: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
  2. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita 2005 [cit. 2017-2-12]. Dostupné z WWW: http://www.svod.cz.
  3. Lukeš P, Zábrodský M, Plzák J, et al. Úloha NBI v endoskopické diagnostice dlaždicových karcinomů hlavy a krku. Endoskopie 2012; 21(1): 16-20.
  4. Sano Y, Kobayashi M, Hamamoto Y, et. al. New diagnostic method based on color imaging using narrowband imaging (NBI) endoscopy system for gastrointestinal tract. Gastrointestinal Endoscopy 2001; 53(5): Abstrakt 3459. Go to original source... Go to PubMed...
  5. Bryan RT, Billingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 2008 Mar; 101(6): 702-705; discussion 705-706. Go to original source... Go to PubMed...
  6. Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int. 2008 Nov; 102(9): 1111-1114. Go to original source... Go to PubMed...
  7. Tatsugami K, Kuroiwa K, Kamoto T, et al. Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer.J Endourol. 2010; 24(11): 1807-1811. Go to original source... Go to PubMed...
  8. Li K, Lin T, Fan X, Duan Y, Huang J.Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Urol. 2013; 20(6): 602-609. Go to original source... Go to PubMed...
  9. Kobatake K, Mita K, Ohara S, Kato M. Advantage of transurethral resection with narrow band imaging for non-muscle invasive bladder cancer. Oncol Lett. 2015; 10(2): 1097-1102. Go to original source... Go to PubMed...
  10. Narrow Band Imaging [online]. Dostupné z (NBI)https://www.olympus.nl/medical/en/medical_systems/applications/urology/bladder/narrow_band_imaging__nbi_/narrow_band_imaging__nbi_.html
  11. Brisuda A, Hrbáček J, Babjuk M. Využití fotodynamické diagnostiky a úzkopásmového zobrazení v diagnostice a léčbě svalovinu neinfiltrujících nádorů močového měchýře. Ces Urol 2013; 17(2): 79-87.
  12. Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005; 96(6): 798-802. Go to original source... Go to PubMed...
  13. Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012; 188(1): 58-62. Go to original source... Go to PubMed...
  14. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013; 64(5): 846-854. Go to original source... Go to PubMed...
  15. Daneshmand S, Schuckman AK, Bochner BH, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014; 11(10): 589-596. Go to original source... Go to PubMed...
  16. Kamphuis GM, de Bruin DM, Fallert J, et al. Storz Professional Image Enhancement System: A New Technique to Improve Endoscopic Bladder Imaging. J Cancer Sci Ther 2016, 8: 3.
  17. Butler HJ, Ashton L, Bird B, et al. Using Raman spectroscopy to characterize biological materials. Nat Protoc. 2016; 11(4): 664-687. doi: 10.1038/nprot.2016.036. Go to original source... Go to PubMed...
  18. Lopez A, Liao JC. Emerging endoscopic imaging technologies for bladder cancer detection. Curr Urol Rep. 2014; 15(5): 406. Go to original source... Go to PubMed...
  19. Shapiro A, Gofrit ON, Pizov G, Cohen JK, Maier J. Raman molecular imaging: a novel spectroscopic technique for diagnosis of bladder cancer in urine specimens. Eur Urol. 2011; 59(1): 106-112. Go to original source... Go to PubMed...
  20. Karl A, Stepp H, Willmann E, et al. Optical coherence tomography for bladder cancer-ready as a surrogate for optical biopsy? Results of a prospective mono-centre study. European Journal of Medical Research. 2010; 15(3): 131-134. Go to original source... Go to PubMed...
  21. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol. 1999; 19(3): 1751-1758. Go to original source... Go to PubMed...
  22. Shariat SF, Bolenz C, Karakiewicz PI, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010; 105(4): 489-495. Go to original source... Go to PubMed...
  23. Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy. Neoplasia. 2010; 12(8): 628-636. Go to original source... Go to PubMed...
  24. Ratert N, Meyer HA, Jung M, et al. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013; 15(5): 695-705. Go to original source... Go to PubMed...
  25. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331(6024): 1559-1564. Go to original source... Go to PubMed...
  26. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11): 1028-1038. Go to original source... Go to PubMed...
  27. Gazzaniga P, de Berardinis E, Raimondi C, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer. 2014; 135(8): 1978-1982. Go to original source... Go to PubMed...
  28. Flaig TW, Wilson S, van Bokhoven A, et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology 2011; 78(4): 863-867. Go to original source... Go to PubMed...
  29. Witjes JA, Compérat E, Cowan NC, et al. Guidelines for muscle invasive and metastatic bladder cancer [online]. Dostupné z WWW: http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.